Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
WRAL Investigates: Why some veterinarians face minor charges for deadly mistakes
Recommended
Map shows parts of western NC open for tourism
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Harbor Disruptive Innovation ETF
(NY:
INNO
)
16.05
+0.15 (+0.97%)
Official Closing Price
Updated: 8:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Harbor Disruptive Innovation ETF
CBD-Focused Innocan Pharma Achieves 4X Revenue Growth In Q1, Hits $6.8M Mark
May 28, 2024
Innocan Pharma's Q1 2024 revenue surged 334% to $6.8M, driven by strong sales growth from BI Sky Global. Read about financial performance.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
April 29, 2024
Pre-market stock movers are a great way to start the week as we check out all of the biggest news moving shares on Monday!
Via
InvestorPlace
This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain
April 23, 2024
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. Food and Drug Administration...
Via
Benzinga
Exposures
Product Safety
534% Revenue Surge Unveiled By Israeli CBD-Focused Pharma Company, Exceeding Expectations
April 02, 2024
Innocan Pharma's 2023 earnings report: Revenue soars 534%, operating loss down 61%, $1.5M capital raise. CEO shares strategic vision.
Via
Benzinga
CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval
February 13, 2024
Cannabinoid-focused pharmaceutical company Innocan Pharma Corp expects preliminary revenues of $4.89m in Q4 of fiscal 2023, representing a YoY increase of 331%. It said preliminary revenues are...
Via
Benzinga
Exposures
Product Safety
Key Leadership Changes In Cannabis You Should Know About As We Head Into 2024
December 22, 2023
This month, the Indigenous Cannabis Industry Association held its first Indigenous Cannabis Regulators roundtable, bringing together Indigenous Cannabis Regulators from Tribal Nations and...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.